← All trials
NCT01990768
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2015
- Primary completion
- Oct 31, 2017
- Completion date
- Dec 31, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 967
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- Oregon Health and Science UniversityOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- American Heart AssociationCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Heart and Stroke Foundation of CanadaCollaborator
- Defence Research and Development CanadaCollaborator
- United States ArmyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.